In vitro bioactivity and degradation behaviour of β-wollastonite derived from natural waste
Abstract
Calcium silicate ceramics, in particular wollastonite (CaSiO3), is the most commonly used bioactive material for bone regeneration and repairing applications. The present study aims to synthesize cost effective wollastonite using natural waste materials such as rice husk ash (RHA) and eggshells, sources of silica and calcium oxide respectively. Wollastonite was prepared by sol-gel method and based on thermogravimetric and differential thermal analysis (TG/DTA) results the samples were sintered at 850 °C. X-ray diffractometer (XRD) revealed that the sintered samples possess single phasic β-wollastonite. The assessment of bioactivity was examined using in vitro studies by immersing the pellets in simulated body fluid (SBF) for different time periods (3, 7, 14, 21 days). The growth of hydroxyapatite layer on the surface of the sample was analysed using XRD, Fourier transform infrared (FTIR) spectroscopy and Scanning electron microscopy-energy dispersive spectrometer (SEM-EDS). The significant change in pH of the SBF solution was observed during the first 11 days of immersion, after which the pH was saturated. Biodegradation test was performed in SBF and Tris buffer solutions according to ISO 10993-14 standard, and the test revealed that the ceramic pellets showed lower degradation rates with slow dissolution of ionic species. MTT assay demonstrated that the prepared wollastonite exhibits cytocompatibility with MG-63 cells at different dosage (1000-50 μg/mL) for 48 h. The…
Read the paper
Related studies
- The Matrisome: In Silico Definition and In Vivo Characterization by Proteomics of Normal and Tumor Extracellular Matrices
- The Escherichia coli MG1655 in silico metabolic genotype: Its definition, characteristics, and capabilities
- In silico pharmacology for drug discovery: methods for virtual ligand screening and profiling
- In silico prediction of splice-altering single nucleotide variants in the human genome
- In silico clinical trials: how computer simulation will transform the biomedical industry
- In silico optimization of a guava antimicrobial peptide enables combinatorial exploration for peptide design
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.